Twitter icon
Brussels IP 2012
OverviewagendaspeakersPartnersCEOsNetworkVerbatimAnnouncementSocial ProgrammeVenueRegistration
Swith to Alicante IP 2012 Patents
Supported by

EPO
WIPO
Business Europe
NYSE Euronext

In association with

Hoyng Monegier

In association with

Qualcomm
Microsoft
Ideas Matter.
CPA Global
Kenyon & Kenyon
CDC propriété intellectuelle
Finnegan

Arnold Siedsma
Sughrue

RWS

Gevers

Valipat
Bourguet avocats
Casalonga & associés
PAPST Licensing
Sisvel

Partners
ACT
Amcham Belgium
ASTP
EuropaBio
GRUR

In association with

WIPR

Managing Intellectual Property

NewEurope
TopLegal
IP Watch
Eureka
IP Magazine
Patent Lawyer Magazine
Brussels Airlines


Researched by

Premier Cercle
Agenda
Download the Full Programme

Countdown D - -2197
December 6 \ Day 1 December 7 \ Day 2
FRIDAY DECEMBER 7 DAY 2
8:00 am
Registration and café d’accueil
mORNING PLENARY KEYNOTES
9:00 am
Introduction
Francis Gurry
Director General WORLD INTELLECTUAL PROPERTY
9:30 am
Keynote address
Benoît Battistelli
President EUROPEAN PATENT OFFICE
10:00 am
Is Intellectual Property Politicizing?
Are political decision-makers really more knowledgeable today about innovation and IP? What are the key drivers of their interests?
ACTA et al.: is IP hated by public masses? Is it well understood? Can opinion be influenced? Which role does media play in this game?
Christian Engström
MEP SWEDISH PIRATE PARTY \ Sweden
Chair
Peter Scott
Managing Editor
WORLD IP REVIEW \ United Kingdom
10:10 am
IP Marketplace:  U.S., Asia & Europe Views
Are the U.S. most seasoned at practicing IP finance as a whole?
China multiple funds, Korea 5-year plan, initiatives in Taiwan and Japan…: are Asian countries better prepared in the race for total innovation?
Is Europe most advanced in co-operative works?
Lawrence Bickers
Head of IP Monetisation COLLER IP MANAGEMENT \ United Kingdom
Emmanuelle Prono
Assistant General Counsel & Director Intellectual Property Techtronic Industries \ Hong Kong
Chair
Raymond Zenkich
Founding Partner
RED CHALK GROUP LLC \ United States
10:30 am
Coffee Break
mORNING WORKSHOPS STREAMS 7–9

7. America Invents Act

8. IP Exploitation

9. Pharma & Biotech

11:00 am
7A Filing Scenarios Before and After March 16, 2013
A summary of implementation rules and practices by the USPTO: how will they impact your organization?
Should you hurry your patents under first-to-file if you are in pharma/biotech?
Are there any ways to prolong filings with the actual system? Which ones?
What will be the impacts of AIA on IP litigation? valuation? monetization? licensing?
Malcolm T. Meeks
Principal, IP Licensing Attorney
INFINEON TECHNOLOGIES AG \ Germany
Prof. Herbert Munsterman
Director & Lecturer, Intellectual Property Management and Markets Program
ILLINOIS INSTITUTE OF TECHNOLOGY \ United States
Chair
Eric Raciti
Partner
FINNEGAN \ Belgium
8A IP Due Diligence: Patent Analysis, Mapping, Visualization
Defining an IP due diligence programme: which tools? When to use them, or not?
Which scope for investigations? How to draft exhaustive checklists
Monitoring & analyzing patent portfolio
Benchmarking with your competitors
How to minimize the risks in IP transactions and avoid costly mistakes
How patent knowledge can help maximize your valuation efforts?
Frédéric Caillaud
Director of Licensing & Business Development
L'ORÉAL \ France
Dr Roya Ghafele
Lecturer
UNIVERSITY OF OXFORD \ United Kingdom
Sertaç Köksaldı
Intellectual Property Manager
ARÇELIK A.Ş. \ Turkey
Chair
Art Nutter
Chief Executive Officer
TAEUS \ United States
9A Litigation Strategies in the Pharma & Biotech Industries
Dealing with transnational cases: best routes for forum shopping based on recent case law
Supplementary protection certificates for new uses & basic patents: legal uncertainties for patentees?
Pharmaceutical companies, generics producers: how to make optimal use of preliminary injunctions
Which litigation risks for generics in their launch phase?
Simon Ayrton
Partner
POWELL GILBERT LLP \ United Kingdom
Dr. Frank Burkert
European Patent Attorney
BAYER HEALTHCARE \ Germany
Jens Toftelund Madsen
European Patent Attorney
H. Lundbeck A/S \ Denmark
Chair
Benoît Strowel
Partner
HOYNG MONEGIER LLP \ Belgium
12:00 pm
7B AIA: the Interactions with PCT and Foreign Prior Art
Are the U.S. closer to harmonization with the European patent systems, present and future?
US PCT applications will be considered as prior art but article 102(b)(2) provides derogations. What is going to change for European companies?
How to prepare for a drastic widening of the scope of prior art searches
Jacques Bauvir
Head of the Intellectual Property Department
MICHELIN \ France
Albert Tramposch
Deputy Executive Director for International and Regulatory Affairs
AIPLA \ United States
Chair
Thomas P. Canty
IP Attorney (USA)  & Member
Leydig, Voit & Mayer, Ltd. \ Germany
8B IPR Portfolio Management: How to Reach Higher Profitability
Best practices and tools for monitoring, valuation, optimization, decision-making
Defining Key Performance Indicators in line with your patent strategies
Sharing data across your organization
Monetization techniques to maximize the value of your IP assets
Financial engineering of royalties and other IP revenue streams
IP outsourcing: how to make it work
Jean-Marc Brunel
Head of Intellectual Property - CIPO
SNECMA-SAFRAN GROUP \ France
Raimondo Coletti
European Patent Attorney
CPA GLOBAL \ United Kingdom
Adrian Spillmann
Head Global Intellectual Property
INTERCELL AG \ Austria
Chair
Patrice Durand
Chief Executive Officer
VALIPAT \ Belgium
9B Stem Cells: Where Do We Stand Now?
Legal consequences of the Brüstle case for the industry, one year on
What are the impacts on examination and grant practices at patent offices
Towards exclusion of funding for stem cells research within the 7th Framework Programme?
Will stem cell research move towards new goals? Can some countries become havens for research?
Chris Alder
Chief Intellectual Property Counsel
OSIRIS THERAPEUTICS \ United States
Dr. Aliki Nichogiannopoulou
Director of Biotechnology
EUROPEAN PATENT OFFICE \ Germany
Clara Sattler de Sousa e Brito
Partner
LIERMANN-CASTELL \ Germany
Chair
Simon Dack
Partner
HOYNG MONeGIER LLP \ The Netherlands
1:00 pm
Lunch \ Networking
  or, by invitation, lunch with Sughrue Mion PLLC (presentation by Ken Burchfiel, Raja Saliba and Chandran Iyer) on
USPTO POST GRANT TRIALS IN THE COURTROOM
AFTERNOON PLENARY KEYNOTES
 
Keynotes moderated by
Aoife White
EU Competition Reporter
Voit & Mayer, Ltd. \ Belgium
2:30 pm
Keynote address
Antitrust vs. IP? Healing the Cleavage
Patents are often called monopolies, or they are leading to them, while antitrust opposes monopolies:
is it too obvious to be true?
There’s no doubt that patents and antitrust are beneficial to the economy:
so, what are the controversies? How to address them appropriately?
Cecilio Madero Villarejo
Deputy Director General for Antitrust, DG Competition EUROPEAN COMMISSION \ Belgium
3:00 pm
Success Story
How to Build a Business Entirely on Patents
Bart Van der Stockt
Managing Director UNILIN, DIVISION TECHNOLOGIES (MOHAWK) \ Luxembourg
3:20 pm
CLOSING COFFEE




 
> To become Partner: Patrice Cros (Brussels), pc@premiercercle.com
> For information about the programme: François Morel (Paris), fm@premiercercle.com
> To register one or more delegates: Bérengère Delescluse (Brussels), bd@premiercercle.com